Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
Annexon (ANNX) is back in focus after the company submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart in Guillain Barre syndrome, marking a key regulatory moment for this clinical program. See our latest analysis for Annexon. The MAA news arrives after a strong 90-day share price return of 92.09% and a 30-day share price return of 17.41%, pointing to building momentum despite a 1-day share price dip of 1.46% and mixed longer term total shareholder returns, including a 44.52% 1-year gain against deeper three and five year declines. If Annexon's recent move has you watching biotech more closely, this could be a useful moment to scan other healthcare stocks that might fit your style and risk tolerance. With the shares at US$6.07, a value score of 2, no revenue yet, and an intrinsic value estimate suggesting a wide gap, the key question is whether the recent excitement leaves Annexon undervalued or already pricing in future growth.
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]Yahoo! Finance
- Annexon (NASDAQ:ANNX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026GlobeNewswire
- Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré SyndromeGlobeNewswire
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 1/14/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/2/26 - Form 4
- ANNX's page on the SEC website